Gastrointestinal Cancer
Specialty Channel

Featured Article
Data from the 2021 ONS Congress reveals the telehealth coordination progress has provided advancements in the Gastrointestinal Medical Oncology Program.
According to data presented at the 2021 ONS Congress, researchers have observed patients with gastrointestinal (GI) cancers experience moderate to high levels of sleep disturbance during chemotherapy…
The FDA has approved nivolumab, in combination with certain chemotherapies, for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal…
The FDA has approved pembrolizumab for the treatment of patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) carcinoma.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.

News

Data from the 2021 ONS Congress reveals the telehealth coordination progress has provided advancements in the Gastrointestinal Medical Oncology Program.
According to data presented at the 2021 ONS Congress, researchers have observed patients with gastrointestinal (GI) cancers experience moderate to high levels of sleep disturbance during chemotherapy…
The FDA has approved nivolumab, in combination with certain chemotherapies, for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal…
The FDA has approved pembrolizumab for the treatment of patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) carcinoma.

Interactive Features

True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
Stay in the know.
OncNet Newsletter